Invesaro

Stocks Health care ONC

NASDAQ · Health care

BeOne Medicines Ltd. (ONC)

BeOne Medicines Ltd. brought in $6.1B of revenue over the twelve months to June 30, 2026, up 34.3% from a year earlier. Net income was $655.7M, a net margin of 10.7%. Operating cash flow minus capital spending left $941.7M of free cash flow in fiscal 2025. At June 30, 2026 it held $5.1B in cash against $788.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.

Free, no password. An email when ONC files with the SEC.

Price
$390.94
-2.19% on the day · November 20, 2026
52-week range $253.95 to $424.73
Market cap
$44.5B
Revenue (last 12 months)
$6.1B
+34.3% year on year
Net margin
10.7%
P/E
2,057.6
on FY2025 diluted EPS

Key facts about BeOne Medicines Ltd.

Net worth
BeOne Medicines Ltd. has a market value (market cap) of $44.5B at the latest share price, and shareholders' equity of $5.2B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit
In fiscal 2025 revenue was $5.3B (+40.2% year on year), with net income of $286.9M. Over the 12 months to June 30, 2026: revenue $6.1B, net income $655.7M.
Cash flow
In fiscal 2025 operations brought in $1.1B of cash; after $185.8M of capital spending, free cash flow was $941.7M.
Latest report
The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 5, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
Next earnings report
BeOne Medicines Ltd.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.

What BeOne Medicines Ltd. does

BeOne Medicines, formerly known as BeiGene, is an oncology biotechnology company that discovers, develops, and commercializes targeted cancer therapies. It develops small-molecule drugs and monoclonal antibodies to treat various hematologic cancers and solid tumors for patients globally. Its shares trade on NASDAQ under the ticker ONC.

Revenue and profit by year

Revenue
FY18: $198.2M $198.2M FY18FY19: $428.2M $428.2M FY19FY20: $308.9M $308.9M FY20FY21: $1.2B $1.2B FY21FY22: $1.4B $1.4B FY22FY23: $2.5B $2.5B FY23FY24: $3.8B $3.8B FY24FY25: $5.3B $5.3B FY25
Net income
FY18: -$673.8M -$673.8M FY18FY19: -$948.6M -$948.6M FY19FY20: -$1.6B -$1.6B FY20FY21: -$1.5B -$1.5B FY21FY22: -$2B -$2B FY22FY23: -$881.7M -$881.7M FY23FY24: -$644.8M -$644.8M FY24FY25: $286.9M $286.9M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$5.3B$447.1M$286.9M$0.19$941.7M
2024$3.8B-$568.2M-$644.8M-$0.47-$633.3M
2023$2.5B-$1.2B-$881.7M-$0.65-$1.7B
2022$1.4B-$1.8B-$2B-$1.49-$1.8B
2021$1.2B-$1.4B-$1.5B-$1.21-$1.6B
2020$308.9M-$1.7B-$1.6B-$1.50-$1.4B

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

A report was expected around November 5, 2026 and is not on file yet.

Estimated from its filing rhythm: 52 weeks after its report of November 6, 2025. Not a date the company has announced. See the report calendar · Earnings, quarter by quarter

Where ONC ranks in Health care

Revenue$5.3B
#63 of 751 in Health care · Top 8%
Revenue growth+40.2%
#108 of 532 in Health care · Top 20%
Net margin5.4%
#163 of 544 in Health care · Top 30%
Free cash flow margin17.6%
#73 of 490 in Health care · Top 15%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What BeOne Medicines Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 16, 2026
  2. August 26, 2026
  3. August 5, 2026
    Quarterly report 10-Q · period to June 30, 2026Revenue rose 30% to $1.7B versus the same quarter last year; diluted EPS $0.16 versus $0.06.
  4. August 5, 2026
  5. June 26, 2026
  6. June 15, 2026
  7. June 11, 2026
  8. June 11, 2026
  9. May 15, 2026
  10. May 14, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on October 2, 2026. Insider transactions on SEC

What is ONC worth? A DCF from its reported cash flow

Insider trades

What the people running BeOne Medicines Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $25.3M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.

Bought (open market)
$0
last 90 days
Sold
$25.3M
last 90 days
Net sold
70,842
$25.3M
DateInsiderWhatSharesPriceValueFiling
September 30, 2026 Lee Chan HenrySVP, General Counsel Soldpre-planned (10b5-1) 1,115 $375.00 $418.1K Form 4
September 28, 2026 Wang XiaodongDirector Exercised options 31,028 $36.90 $1.1M Form 4
September 28, 2026 Wang XiaodongDirector Soldpre-planned (10b5-1) 160 $356.97 $57.1K Form 4
September 28, 2026 Wang XiaodongDirector Soldpre-planned (10b5-1) 120 $358.71 $43K Form 4
September 28, 2026 Wang XiaodongDirector Soldpre-planned (10b5-1) 40 $359.16 $14.4K Form 4
September 28, 2026 Wang XiaodongDirector Soldpre-planned (10b5-1) 2,241 $361.05 $809.1K Form 4
September 28, 2026 Wang XiaodongDirector Soldpre-planned (10b5-1) 4,239 $362.17 $1.5M Form 4
September 28, 2026 Wang XiaodongDirector Soldpre-planned (10b5-1) 3,499 $363.10 $1.3M Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns ONC

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
Julian C. Baker13D, may seek influence with 4 related filers 7.8% 115,912,814 September 16, 2026

Latest filings below 5%: Capital International Investors 4.2% (May 14, 2026); HHLR Advisors, Ltd. 4.9% (May 13, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

15 insiders reported holding 22,855,641 shares in total, about $8.94B at the last price.

HolderSharesAs of
Baker Bros. Advisors LPDirector 8,260,7298,260,729 held indirectly September 14, 2026
Oyler JohnChief Executive Officer, Director 5,697,649 August 12, 2026
Wang XiaodongDirector 4,682,493 September 28, 2026
Wang LaiPresident, Global Head of R&D 1,710,085 June 23, 2026
Wu XiaobinPresident and COO 1,308,161 August 25, 2026
Rosenberg AaronChief Financial Officer 397,891 August 3, 2026
Lee Chan HenrySVP, General Counsel 346,554 September 30, 2026
Ball Titus B.Principal Accounting Officer 99,645 September 1, 2026
Hooper Anthony CDirector 83,720 June 11, 2026
Riva AlessandroDirector 73,164 June 11, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about ONC

What does BeOne Medicines Ltd. do?

BeOne Medicines, formerly known as BeiGene, is an oncology biotechnology company that discovers, develops, and commercializes targeted cancer therapies. It develops small-molecule drugs and monoclonal antibodies to treat various hematologic cancers and solid tumors for patients globally. Its shares trade on NASDAQ under the ticker ONC.

What is BeOne Medicines Ltd.'s net worth?

BeOne Medicines Ltd. has a market value (market cap) of $44.5B at the latest share price, and shareholders' equity of $5.2B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is BeOne Medicines Ltd. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $655.7M on revenue of $6.1B, a net margin of 10.7%.

How much revenue does BeOne Medicines Ltd. make?

Over the twelve months to June 30, 2026 BeOne Medicines Ltd. reported revenue of $6.1B. That is 34.3% more than a year earlier.

When did BeOne Medicines Ltd. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 2, 2026.

When is BeOne Medicines Ltd.'s next earnings report?

BeOne Medicines Ltd.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.

Similar companies

Compare ONC with

Compare ONC with any company

Follow ONC

Get an email when BeOne Medicines Ltd. files with the SEC: results, executive changes, material agreements and annual reports.

Free, no password. An email when ONC files with the SEC.

Where the numbers come from

Financial figures are the values BeOne Medicines Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.